Lupin’s generic antibiotic gets USFDA OK

Pharmaceutical firm Lupin Ltd,today said it has received final approval from the US health regulator for its generic antibiotics minocycline hydrochloride extended-release tablets used for treating acne.

Pharmaceutical firm Lupin Ltd,today said it has received final approval from the US health regulator for its generic antibiotics minocycline hydrochloride extended-release tablets used for treating acne.

The approval by the US Food and Drug Administration (USFDA) has been granted to the company’s subsidiary,Lupin Pharmaceuticals Inc for tablets of 65 mg,80 mg,105 mg and 115 mg strengths,the company said in a statement.

The tablets are generic versions of Medicis Pharmaceutical Corporation’s patented drug Solodyn,the company said.

Story continues below this ad

It is an oral antibiotic approved to treat only the red,pus-filled pimples of moderate to severe acne in patients 12 years of age and older,it said.

Citing market research firm IMS’ September 2011 data,the company said Solodyn had sales of USD 750 million.

Lupin Ltd scrips were trading at Rs 467.20 per share,on the BSE,up 0.24 per cent from the previous close.

Company INFO More on Lupin

Stocks More on Lupin

Tags:
business news

Donald Trump may replace H-1B lottery with wage-based selection process

World8 hr ago

Days after hiking the fees for new H-1B applications to $100,000, the Donald Trump administration has proposed to overhaul the visa process for high-skilled non-immigrant workers. The Trump administration has suggested a wage-based selection process for the H-1B programme, instead of the current lottery system.

View all shorts

Live Blog